G. Catalano

Publications174
h-index37
Citations4,661
Highly Influential Citations118
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Cascinu
  • 772 Publications • 15,323 Citations
  • D. Cunningham
  • 333 Publications • 23,617 Citations
  • S. Barni
  • 728 Publications • 14,751 Citations
  • P. Rougier
  • 411 Publications • 33,008 Citations
  • Publications
  • Influence
Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
PURPOSE We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of oxaliplatin-induced neurotoxicity. PATIENTS AND METHODS… Expand
  • 362
  • 9
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks… Expand
  • 143
  • 6
Hepatocyte growth factor and macrophage inflammatory protein 1 beta: structurally distinct cytokines that induce rapid cytoskeletal changes and subset-preferential migration in T cells.
T-cell migration into tissue depends on a cascade of rapid and selective adhesive interactions with endothelium. "Triggering" is a step in that cascade required to activate T-cell integrins.… Expand
  • 133
  • 6
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer.
BACKGROUND Docetaxel has shown some activity in advanced gastric cancer. Recent phase I studies found low hematologic toxicity and a favourable toxicity profile when docetaxel was administered on a… Expand
  • 85
  • 5
Phase II study of paclitaxel in pretreated advanced gastric cancer
Patients with advanced gastric cancer unresponsive or progressing after PELF chemotherapy (5-fluorouracil, leucovorin, cisplatin and epidoxorubicin) received paclitaxel at the dose of 225 mg/m2 every… Expand
  • 99
  • 5
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
The usefulness of chemotherapy in patients with stage II disease continues to be debated. Biological prognostic factors may allow further insight into the optimal treatment strategy for patients with… Expand
  • 212
  • 4
  • PDF
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients.
STUDY OBJECTIVE To investigate the prognostic significance of interleukin (IL)-10 serum levels in advanced non-small cell lung cancer (NSCLC) patients. DESIGN IL-10 serum levels were measured… Expand
  • 127
  • 4
  • PDF
Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.
PURPOSE We performed a randomized double-blind placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of cisplatin (CDDP)-induced neurotoxicity. PATIENTS AND METHODS… Expand
  • 114
  • 4
Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.
Serum levels of interleukin-6 (IL-6) were evaluated in a group of advanced non-small cell lung cancer (NSCLC) patients using an enzyme-linked immunosorbent assay. The data were related to clinical… Expand
  • 70
  • 4
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with…
Tumours of patients with node-positive rectal cancer were studied by immunohistochemistry for p53, BAX and vascular endothelial growth factor expressions. Results were correlated to the relapse rate,… Expand
  • 50
  • 4
...
1
2
3
4
5
...